Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

THERESA PCP · Pre-Comercial Procurement of innovative and sustainable solutions to Treat HEalthcaRE System wAstewater

HORIZONStatus: SIGNED1 September 202531 August 2029EU funding €5,287,206Call HORIZON-HLTH-2024-CARE-14

Hospital wastewater (HWW) poses a significant environmental and health risk due to the presence of pharmaceuticals, pathogens, and other hazardous substances that are administered in healthcare institutions. Unfortunately, current urban wastewater treatment (WWT) plants are not capable of effectively removing many of the pollutants generated by hospitals. As a result, these contaminants reach and accumulate in natural water bodies, threatening ecosystems and biodiversity, and public health through the contamination of drinking water or food. In addition, public health is also menaced by HWW as it contains important amounts of antibiotic-resistant microorganisms and genes. In fact, Antimicrobial Resistance (AMR) is one of the greatest health threats of our times.While most common medicines are consumed in households, specialized drugs such as cytostatic drugs, some antibiotics, or X-ray contrast agents are mainly distributed in hospitals. Furthermore, HWW is a hotspot for the transmission of antibiotic-resistant bacteria (ARB) and antibiotic-resistant genes (ARG). To reduce the risk associated to these contaminants, it is key to remove them as close to their source as possible, and before they are discharged to the municipal water network. Despite the existence of different technologies that efficiently remove contaminants from HWW, currently, there is no single process that can be used for the comprehensive treatment of HWW regarding the elimination of a mix of pollutants to a high degree.Moreover, technology may be further developed to be more efficient, environmentally sustainable, and cost-effective for hospitals. In this context, the main objective of THERESA PCP is to launch a pre-commercial procurement process (PCP) based on the development of an environmentally sustainable on-site system to decontaminate HWW, being capable of effectively removing, among other contaminants, cytostatic drugs, X-ray contrast agents, antibiotics, ARB and ARG, from HWW.

Consortium · 17 organisations

coordinator

FUNDACION PUBLICA MIGUEL SERVET

ES · €3,352,863

participant

WOJEWODZKI SZPITAL SPECJALISTYCZNY W OLSZTYNIE

PL · €206,688

participant

SCIENCE & INNOVATION LINK OFFICE SL

ES · €84,375

participant

INSTYTUT EKOLOGII TERENOW UPRZEMYSLOWIONYCH

PL · €106,250

participant

SCIENCE UNION FOR INNOVATION

ES · €231,250

thirdParty

CORVERS IBERIA SL

ES

thirdParty

UNIVERSITEIT MAASTRICHT

NL

participant

ZIEKENHUIS AAN DE STROOM

BE · €144,688

participant

TICBIOMED TECNOLOGIAS DE LA INFORMACION PARA LA SALUD EN LA REGION DE MURCIA ASOCIACION

ES · €112,500

participant

CONSORCI HOSPITALARI DE VIC

ES · €145,625

thirdParty

CORVERS GREECE MONOPROSOPI I.K.E.

EL

participant

ACADEMISCH ZIEKENHUIS MAASTRICHT

NL · €224,063

participant

SIHTASUTUS POHJA-EESTI REGIONAALHAIGLA

EE · €216,250

participant

CORVERS PROCUREMENT SERVICES BV

NL · €189,375

participant

HEALTH CARE WITHOUT HARM EUROPE

BE · €101,250

thirdParty

SERVICIO ANDALUZ DE SALUD

ES

participant

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.

ES · €172,031

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.